Chaep Stocks, 9/23/2011 Update

All of last weeks gains evaporated this week.

Note that Interactive Brokers imposed new margin requirements that went into effect last week and will continue to have impact through next week. They raised their margin requirements to 100% on stocks trading with a market cap under $250 million. This has had some extra impact on small cap stocks on top of the lousy market. They also did this to Chinese stocks (including our LTUS) in April of this year.

Some of our stocks are just stupid cheap—compared to their cash on hand. Check the list in our posting of 9/2/2011.

We are therefor doubling up on GRVY. New average buy price will be $1.45. Also double up on BVSN. New average buy price will be $10.84. Lastly add another $10,000 to MITL. New average buy price will be $3.04.

We were down 4.6% last week and are now down 7.4% for the year.

The DOW was down 6.4% last week, NASDAQ was down 5.3% and the S+P 500 was down 6.5%. The Russell 3000 was down 6.9%.

AVSO, BVSN, CCUR, EXTR, RIMG, MTSL and MITL are our favorites.

For the year, the DOW is down 7%, NASDAQ is down 6.4%, S+P 500 is down 9.6%, the Russell 3000 is down 10.5%

Last week we went 6 stocks up, 14 down and 1 unchanged. Since inception we are now 48 stocks up and 23 down for a 70% winning percentage (80% is our target win %).

Since our beginning, we have closed out the following positions:

2006-NTCT +44%
2006-ONXS +11% (Buyout offer)
2006-DTLK +41%
2006-CAW +21% (Buyout offer)
2007-IYXI.ob +44% (Buyout offer)
2007-MOBI +47% (Buyout offer)
2007-INFT +11% (Buyout offer)
2007-RITT +62%
2007-MIVA +55%
2007-DTLK +25% (2 weeks)
2007-PDLI + 3%
2007-QADI +25%
2007-CIMT +50%
2007-BDR +19%
2007-LINN.ob -57% (mortgage business bust didn’t help here)
2007-TISA -39% (take some tax loss for 2007 due to disappointing results.
2008-ANGN +26%
2008-OPTO.ob +40% (Buy-out offer)
2008-PDLI +9% (company split, and special dividend)
2008-BDAY -39% (long overdue takeover offer-or “take-under”)
2008-DTLK +40% (third trip on this one)
2008-ILOG +26% (Buy-out offer from IBM)
2008-PARL +56%
2009-MBRK +67%
2009-SNWL +14%
2009-CYNO +25%
2009-DTLK +33%
2009-NED +46%
2009-CUTR +13%
2009-HSTM +67% (continued good earnings)
2009-RNWK +36%
2009-OPK +116%
2009-CLZR -32% (a loser even on a buy-out)
2009-DTLK +28% (our 5th profitable trip on this one)
2010-HPOL +110%
2010-DIVX +25%
2010-CHRD +37% Buyout (2 weeks after we recommended it)
2010-HPOL +30%
2010-MGIC +82%
2010-GSL +78%
2010-CCEL +49%
2010-HPOL +27%
2010-CAW EVEN (excluding 2.5 years of dividends)
2011-DWCH +116%
2011-IPAS +15%
2011-PRM +56% Buyout (1 week after we recommended it)
2011-RST +12%
2011-NINE -10%

The model portfolio assumes $10,000 invested in each stock (unless we double-up–then it is $20,000), less $10 commission each way (TD Ameritrade rate).

For the 48 stocks that we closed out since 2006 (43 were winners) the average net gain was 37%.

Sigma Designs Inc. (NASDAQ-SIGM)-Recommended 7/11/2011)
Buy Price-$8.49
Valuation $13.40 (Was $16.02)
Closed down $.55 at $7.99
Earnings out in August. Sales were down 23% to just under $47 million and they lost $22 million. Yuck. But it is not as bad as it seems. Cash and investments actually went up to $5.40 a share ($170 million) and if you exclude the GAAP non-cash BS and the inventory write down, the loss was “only” about $6 million. So we are trading at a market cap of about $65 million (excluding cash) for a $200 million a year chip company with 50% margins. Still pretty stupid we think. However, our valuation dived to $13.40, so we need to keep our eye on this one.
Down 6%, HOLD

Mitel Networks (NASDAQ-MITL)-Recommended 7/6/2011)
Buy Price- $3.36( Was $3.95 before $10,000 added)
Valuation $14.04 (Was $10.39)
Closed down $.60 at $2.55
Earnings in August. Pretty good. Revenues were $164 million up from $160 million last year. Non-GAAP net income was $9.2 million or $.16 a share compared to $10.8 million and $.19 a share last year. They took a 44.8 million restructuring charge in the quarter, to they reported a loss of $2.8 million in the quarter.
Our valuation jumped to $14.04.
Down 24%, BUY

Rimage (NASDAQ-RIMG)-Recommended 5/24/2011)
Buy Price-$14.20
Valuation $25.63 (Was $26.45)
Closed down $.77 at $13.25
Yield here is 3% and cash is 94% of its market cap.
Arcadia is pushing again. They sent a letter to Rimage on September 12th, again asking for the $9 dividend and making vague threats of doing something. Not clear what exactly. Oust the CEO, make a tender offer are among the possibilities we guess.
Earnings out in July. Sales were off about 10% to $20.2 million and earnings were off $.10 to $.12 per share. Cash continued to rise to $119 million ($12.49 per share). Our valuation slipped a bit to $25.63 on the lower sales. With the 2.6% dividend and a huge cash cushion, we still like RIMG.
Their activist shareholder Arcadia Capital Management sent a letter to the Board in July, suggesting that RIMG should pay out a $9 per share special dividend, and not waste it on some stupid acquisition. We would take the dividend—or a buy-out.
Down 7%, HOLD

Lexmark International (NYSE-LXK)-Recommended 5/24/2011)
Buy Price-$28.80
Valuation $79.12 (Was $63.99)
Closed down $3.46 at $28.03
Earnings in July. They were great. They made $1.27 per share earnings on flat sales up from $1.07 in earnings last year. They are projecting $.86-$.96 in earnings for Q3. They seem easily on track to make over $4 per share this year. Our valuation soared to $79.12 per share. PE guys should be drooling over LXK. This would normally be a “buy” with such a huge discount to our valuation, but the vagaries on the stock analysts make us cautious.
Down 3%, HOLD

MER Telemanagement (NASDAQ-MTSL)-Recommended 5/17/2011)
Buy Price-$1.42 (Was $1.50 before adding another $10,000 investment)
Valuation $5.61 (Was $5.11)
Closed down $.19 at $1.23
MER announced a contract extension in August of $2.5 million (minimum). This is almost 50% of MER’s entire market cap.
Earnings in August. Not bad. Sales were just over $3 million and they made over $200,000 or $.05 a share. For the six months they have made $.08 a share (untaxed of course). So MTSL is trading at about 8X untaxed annualized earnings. Oh yeah, they have $.63 a share in cash also (up from $.60 last quarter). Our valuation jumped to $5.61 per share.
Down 13% BUY

Harris Interactive (NASDAQ-HPOL)-Recommended 3/3/2010)
Buy Price-$.92
Valuation $2.63 (Was $2.97)
Closed at $.62, down $.05
New CEO is cleaning up. They are closing their Hong Kong, Singapore and Shanghai offices and downsizing their U.K. office. Their will be a restructuring charge in the September quarter of some amount. Nevertheless this will all help to reduce their losses going forward and get this ready to sell.
Old CEO was booted in June and a turnaround guy made CEO. This is good news. He has sold his previous companies.
Latest earnings were not good. Sales fell 7% and they lost $2.3 million or $.04 per share. Our valuation fell to $2.63 per share, still 4X the current price.
Down 33%, HOLD

Concurrent Computer (NASDAQ-CCUR)-Recommended 2/4/2011)
Buy Price-$5.08
Valuation $14.04 (was $18.54, $15.99)
Closed down $.31 at $5.40
Earnings out in August. Sales were down to $15.1 million from $17.3 million and they lost $1.353 million or $.16 a share. Cash per share rose to $3.95 from $3.41. Not a great quarter, but not horrible with the cash rise. Our valuation fell to $14.04-still more than double the current price, and with a huge cash cushion.
In April the company announced that it would not do the stock buy back that Skellig was suggesting. We don’t like buy backs anyway. Hopefully Skellig will keep pushing management to get the share price up. Their ownership is up to 5.86%.
Up 6%, BUY

Astex Pharmaceuticals Inc. (Was SuperGen Inc.) (NASDAQ-ASTX)-Recommended 10/4/2010)
Buy Price-$2.31 (was $2.09 before adding $10,000)
Valuation $3.11 (was $5.21, $4.89, $4.37, $3.48)
Closed down $.32 at $1.89
Earnings out in July. Despite that the quarter results did not include the results of Astex, they provided good guidance of what the second half’s combined results will be. For the latest quarter, revenue rose to $11.7 million from $9.9 million last year and they made $.01 a share versus $.02 last year. This quarter’s results included $1.3 million of expenses related to the merger. So all in all, it was a good quarter. However, our valuation based on this quarter fell to $3.11 as revenues declined from the prior quarters $17 million.
As we suspected, the merger with the revenue poor Astex will hurt our valuation which does not take into account the massive drug pipeline of Astex. It is not easy to find a small drug company that has a pile of cash, is not losing a ton of money and is trading at even close to our valuation.
There are $2 BILLION of potential milestone payments down the road.
Down 18%, HOLD

Performance Technology (PTIX-Recommended 3/30/2010)
Buy Price-$2.70
Valuation $4.87-(was $4.99, $3.79, $3.87, $5.03, $5.98, $7.13)
Closed down $.25 at $1.75
Earnings out in August. Sales up 15% to $8.5 million and they made $300,000 on a non-GAAP basis. Not bad at all. Cash is $1.23 a share and our valuation fell a tad to $4.87
We think we will hold on to this one a bit longer and see if they can get to a consistent profit.
Down 35%, HOLD

Extreme Networks (EXTR-Recommended 3/22/2010)
Buy Price-$3.18 (Was $3.04 before adding another $10,000)
Valuation-$6.45 (was $5.67, $7.36, $7.23, $7.31, $6.82, $6.81)
Closed down $.18 at $2.64
Earnings out in August. Sales rose about 5% from last year to $89 million and they lost $2 million or $.02 a share after about $4 million of non-cash charges. Cash stayed at about $147 million or $1.59 per share. Our valuation moved back up to $6.45 a share.
Big news in July. EXTR announced they are laying off 16% of their employees and expect $20 million of cost reductions in FY 2012 and allow the company to make consistent double digit operating income. We view this all as good news for the future. Starboard was cleared to buy up to 15% of EXTR as disclosed in an SEC filing in June.
Starboard Value Fund filed another 13D/A in June disclosing that they had upped their stake again to 9.6%.
Down 17%, BUY

Broadvision (BVSN-Recommended 3/16/2010)
Buy Price-$13.50
Valuation $18.01-(was $21.21, $22.95, $22.31, $21.77, $23.37, $27.15)
$13.14 per share in cash.
Closed up $.48 at $9.05
Now trading $4.36 below cash value. Nuts.
Marlin Capital Investment bought 248,000 shares on September 16th as reported in their Form 13g this week. Finally somebody has noticed how cheap this is!
Earnings in July. Not so hot. Sales were down to $4 million (from $5.1 million last quarter), and they lost $1.5 million. Cash per share fell to $13.14. Clearly their social networking initiative has not taken hold yet. This is still trading like a Chinese stock, but it is a U.S. company and it trading at less than cash value. Our valuation however fell to $18.01. Without the fact that BVSN is trading at less than cash, we would likely sell BVSN but will hold on another quarter or two and see if they can produce some decent results.
Down 33%, BUY

Gravity Company Ltd. (GRVY-Recommended 1/18/2010)
Buy Price-$1.68
Valuation $5.33-(Was $5.61, $5.73, $4.38, $4.44, $5.15)
Closed down $.12 at $1.28
Now trading at $.82 less than cash value. And they are profitable.
June quarterly earnings out in August. Revenues were just under $14 million and they made $.06 a share. Only fly in the ointment was that Ragnarok 2 is delayed until at least Q1 2012. Cash per share rose to $2.10.
Our valuation fell a bit to $5.33 on some margin compression, but at less than cash value and 30% of our valuation this is one good lottery ticket if they ever release Ragnarok 2.
Down 24%, BUY

AEterna Zentaris (AEZS-Recommended 6/20/2009)
Buy price $1.42 (was $1.78 before adding another $10,000, $1.82 before double up)
Valuation –Speculation.
Closed down $.23 at $1.65
AEZS announced positive Phase 2 results for AEZS 108 in September. Didn’t seem to matter to investors and we actually lost $.05.
Earnings announced in August. Revenues were up about $900,000 to $6.5 million and their operating loss was about $8 million (compared to $15 million loss last year). AEZS has been diligently selling shares under their announced programs and have about $53 million in cash (but close to 100 million shares outstanding). This is pretty normal for a developing drug company.
Speculative for sure.
Up 16%, HOLD

Spectranetics (SPNC-Recommended 9/2/2006)
Buy price $5.68 (was $8.90, $9.40 before adding $10,000, and was $10.65 before double up),
Valuation –$10.00
Closed up $.17 at $6.89
Earnings out in July. Sales rose 7% to $32.2 million and they actually managed a $.02 profit. Cash rose to $35.7 million.
SPNC announced recently that they finally hired a new CEO. He comes from DaVita, but we were not all that impressed with his resume. I hope he is planning on making a big killing on his stock options at SPNC and not just continuing to screw up like the other current and previous management.
Paragon filed a 13D/A in May disclosing they had upped their stake to 7%.
Up 21%, HOLD

Mediware (MEDW-Recommended 6/4/2007)
Buy Price $6.33, (was $6.52, $6.67 ($10,000 added), $6.98 after double up)
Valuation $18.34 (was $16.07, $15.04, $14.23, $15.02, $14.35, $12.13, $12.57, $12.29, $11.90, $11.30, $11.48, $11.47 $10.99, $10.28, $13.32, $12.89, $13.40)
Closed down $.02 at $11.08
Earnings out in September. Revenues up 20% and EPS more than doubled to $.25 a share. Cash remained at $3.66 a share and our valuation jumped to $18.34.
Constellation resumed selling in early September.
We give up on the sale of the company anytime soon.
Constellation Software owns 21.8%, but put itself up for sale this year. Should have bought Constellation stock, it has tripled since they got into MEDW!
All we read is that medical records will be a hot area, so MEDW looks like the place to be.
Up 75%, HOLD

Vertro (VTRO (was-MIVA)-Recommended 10/21/2007)
Buy Price $8.15 (Was $11.90 before adding another $20,000, $13.10 before another $10,000 and was $15.00 before double up),
Valuation $10.91 (was $12.42, $14.23, $14.76, $12.40, $12.55, $10.85, $8.25, $9.45, $28.05, $32.10, $34.20, $37.90, $37.95)
Closed up $.07 at $1.84
VTRO announced in September that their new homepage was generating 30% higher revenue per install. They needed some good news here.
Earnings announced in August. Not great. Sales were down $1 million from last year to $7.5 million and they lost $300,000 ($.05 per share).
Should have sold this when it traded over $6. Our valuation fell to $10.91 and cash per share fell to $.67.
Down 78% HOLD

Angeion Corporation (ANGN-Recommended 8/28/2008)
Buy Price-$3.82 (was $5.15 before $10,000 added)
Valuation $13.13 (was $13.19, $13.60, $15.00, $13.06, $12.15, $11.29, $11.73, $11.47, $11.16, $9.53, $13.30, $13.03)
Closed up $.02 at $4.35
CEO bought 10,000 shares in September at $4.25. Good sign.
Earnings in August. Another lackluster quarter. Sales fell from $7.1 million to $6.8 million and they lost $81,000 or $.02 a share. Our valuation fell slightly to $13.13 and cash was $2.39 per share. If this company could just show a bit of growth I think we would see $10 in short order—if.
Blueline Partners still owns 7.6% of ANGN and ought to be pushing on the company to do something about the stock price.
Up 14%, BUY

OB-abies (Bulletin Board Listed Stocks)

As proven by OPTIO, patience is necessary with these stocks.

ARI Networks (ARIS.ob-Recommended 8/19/2006)
Buy price $1.61 (Was $1.78 before another $10,000 added, was $2.06 before double up),
Valuation $5.65 (was $5.39, $4,86, $5.60, $5.73, $5.54, $5.74, $5.96, $4.72, $5.19, $5.66, $5.63, $5.61, $5.71, $5.49, $5.34, $5.03, $5.28, $5.28, $5.21)
Closed at $.95 up $.15.
Earnings out in June. Sales were flat at $5.354 million, operating income however jumped to $675,000 from $297,000 and they made $.07 per share (about $.04 excluding non-recurring and discontinued operations). Our valuation jumped back up to $5.65 on higher than expected margins. If they can maintain $.04 per quarter (fully taxed), we should be on our way to having a winner here.
Wake up management–you have a great little company here worth 6X what it is selling for.
Now down 41%, BUY, Still a Huge valuation gap here.

Rand Worldwide (RWWI.ob (Was Avatech, AVSO.ob)-Bought November 28, 2005)
Buy price $.79 (Was $.93, $.99 and $1.19 before adding $10,000-each time),
Valuation $2.60 (was $2.40, $1.90, $2.26 $3.07, $3.03, $2.38, $2.57, $2.81, $2.78, $3.30, $3.76, $4.00 $3.41, $3.05, $2.53, $3.25, $3.29 $2.69, $3.36, $3.81)
Stock closed at $.70, down $.05
Next earnings due out Wednesday, September 28th, before the market opens.
Last earnings out in May. Sales were $27.4 million and they made $.04 a share. Our valuation jumped to $2.60 a share. Hopefully another quarter or two of positive results will get this over $1.50.
Down 5%, HOLD

CTI Holdings (CTIG.ob-Recommended 2/25/2006)
Buy price $.27 ask,
Valuation $1.23 (Was $.91, $1.21, $.71, $.83, $.88 $.96, $.93, $.75, $.85, $1.57, $1.40, $1.29, $1.38, $1.31, $1.38, $1.29, $1.42, $1.28 $1.13, $1.05, $.82)
Ask price $.105, closed at $.105.
CEO bought more shares two weeks ago, about 40,000 in total.
One of CTI’s directors bought 254,000 shares in August and the CEO bought 38,000 more. Finally, some trading activity!
Earnings announced in August. Not bad at all. .Revenues increased from $3.578 million to $4 million and they only lost $.01 per share. The good news is that they got a $7 million prepayment on a big U.K. order and were able to pay off all their debt and end up with $4.65 million in net cash. This is $.16 a share—double the current trading price. VOIP revenues more than doubled to $461,000 from $197,000 last year and almost doubled from $246,000 last quarter. VOIP still lost $545,000 but the loss was $100,000 less than last year. Our valuation spiked back up to $1.23.
At a $2.5 million market cap, this is stupidly cheap. Their intellectual property is probably worth 10 times this price. They need to liquefy this value somehow.
They might have to sell or shut this VOIP business down in our opinion. Just losing too much money, and eroding shareholder value–or it could be a home run.
Still an “undercover” company and stock.
Down 61%. HOLD

Lotus Pharmaceuticals (LTUS.ob-Recommended 12/3/2007)
Buy price $1.68 (Was $1.80 before $10,000 adder, $2.16 before double-up)
Valuation-$1.05 (Was $2.43, $4.11, $4.84, $4.98, $4.60, $3.82, $4.00, $3.68, $3.12, $3.98, $4.44, $3.22, $2.12, $4.56, $4.16)
Closed at $.38, up $.01.
Last earnings report in August. Sales were down $200,000 to $18.7 million and they made $.06 a share compared to $.24 last year. Our valuation plunged to $1.05 per share on margin and income declines. Gross margins fell to 26% from 48% last year. We are now worried for the first time that with the decline in net income, that they may be having liquidity issues with all of their capital commitments. If this is going to work, it won’t be until 2012 that we see anything.
Down 78%, HOLD

Advertisements

Cheap Stocks, 9/16/2011 Update

Good week in the market but only an OK week for us.

Some of our stocks are just stupid cheap—compared to their cash on hand. Check the list in our posting of 9/2/2011.

We were up 3% last week and are now down 2.8% for the year.

The DOW was up 4.7% last week, NASDAQ was up 6.2% and the S+P 500 was up 5.4%. The Russell 3000 was up 5.4%.

AVSO, BVSN, CCUR, EXTR, RIMG, MTSL and MITL are our favorites.

For the year, the DOW is down .6%, NASDAQ is down 1.2%, S+P 500 is down 3.3%, the Russell 3000 is down 3.9%

Last week we went 12 stocks up, 6 down and 3 unchanged. Since inception we are now 50 stocks up and 21 down for a 73% winning percentage (80% is our target win %).

Since our beginning, we have closed out the following positions:

2006-NTCT +44%
2006-ONXS +11% (Buyout offer)
2006-DTLK +41%
2006-CAW +21% (Buyout offer)
2007-IYXI.ob +44% (Buyout offer)
2007-MOBI +47% (Buyout offer)
2007-INFT +11% (Buyout offer)
2007-RITT +62%
2007-MIVA +55%
2007-DTLK +25% (2 weeks)
2007-PDLI + 3%
2007-QADI +25%
2007-CIMT +50%
2007-BDR +19%
2007-LINN.ob -57% (mortgage business bust didn’t help here)
2007-TISA -39% (take some tax loss for 2007 due to disappointing results.
2008-ANGN +26%
2008-OPTO.ob +40% (Buy-out offer)
2008-PDLI +9% (company split, and special dividend)
2008-BDAY -39% (long overdue takeover offer-or “take-under”)
2008-DTLK +40% (third trip on this one)
2008-ILOG +26% (Buy-out offer from IBM)
2008-PARL +56%
2009-MBRK +67%
2009-SNWL +14%
2009-CYNO +25%
2009-DTLK +33%
2009-NED +46%
2009-CUTR +13%
2009-HSTM +67% (continued good earnings)
2009-RNWK +36%
2009-OPK +116%
2009-CLZR -32% (a loser even on a buy-out)
2009-DTLK +28% (our 5th profitable trip on this one)
2010-HPOL +110%
2010-DIVX +25%
2010-CHRD +37% Buyout (2 weeks after we recommended it)
2010-HPOL +30%
2010-MGIC +82%
2010-GSL +78%
2010-CCEL +49%
2010-HPOL +27%
2010-CAW EVEN (excluding 2.5 years of dividends)
2011-DWCH +116%
2011-IPAS +15%
2011-PRM +56% Buyout (1 week after we recommended it)
2011-RST +12%
2011-NINE -10%

The model portfolio assumes $10,000 invested in each stock (unless we double-up–then it is $20,000), less $10 commission each way (TD Ameritrade rate).

For the 48 stocks that we closed out since 2006 (43 were winners) the average net gain was 37%.

Sigma Designs Inc. (NASDAQ-SIGM)-Recommended 7/11/2011)
Buy Price-$8.49
Valuation $13.40 (Was $16.02)
Closed up $.58 at $8.54
Earnings out in August. Sales were down 23% to just under $47 million and they lost $22 million. Yuck. But it is not as bad as it seems. Cash and investments actually went up to $5.40 a share ($170 million) and if you exclude the GAAP non-cash BS and the inventory write down, the loss was “only” about $6 million. So we are trading at a market cap of about $65 million (excluding cash) for a $200 million a year chip company with 50% margins. Still pretty stupid we think. However, our valuation dived to $13.40, so we need to keep our eye on this one.
Up 1%, HOLD

Mitel Networks (NASDAQ-MITL)-Recommended 7/6/2011)
Buy Price- $3.36( Was $3.95 before $10,000 added)
Valuation $14.04 (Was $10.39)
Closed up $.08 at $3.15
Earnings in August. Pretty good. Revenues were $164 million up from $160 million last year. Non-GAAP net income was $9.2 million or $.16 a share compared to $10.8 million and $.19 a share last year. They took a 44.8 million restructuring charge in the quarter, to they reported a loss of $2.8 million in the quarter.
Our valuation jumped to $14.04.
Down 6%, BUY

Rimage (NASDAQ-RIMG)-Recommended 5/24/2011)
Buy Price-$14.20
Valuation $25.63 (Was $26.45)
Closed up $1.01 at $14.02
Yield here is 2.9% and cash is 88% of its market cap.
Arcadia is pushing again. They sent a letter to Rimage on September 12th, again asking for the $9 dividend and making vague threats of doing something. Not clear what exactly. Oust the CEO, make a tender offer are among the possibilities we guess.
Earnings out in July. Sales were off about 10% to $20.2 million and earnings were off $.10 to $.12 per share. Cash continued to rise to $119 million ($12.49 per share). Our valuation slipped a bit to $25.63 on the lower sales. With the 2.6% dividend and a huge cash cushion, we still like RIMG.
Their activist shareholder Arcadia Capital Management sent a letter to the Board in July, suggesting that RIMG should pay out a $9 per share special dividend, and not waste it on some stupid acquisition. We would take the dividend—or a buy-out.
Down 1%, HOLD

Lexmark International (NYSE-LXK)-Recommended 5/24/2011)
Buy Price-$28.80
Valuation $79.12 (Was $63.99)
Closed up $1.07 at $31.49
Earnings in July. They were great. They made $1.27 per share earnings on flat sales up from $1.07 in earnings last year. They are projecting $.86-$.96 in earnings for Q3. They seem easily on track to make over $4 per share this year. Our valuation soared to $79.12 per share. PE guys should be drooling over LXK. This would normally be a “buy” with such a huge discount to our valuation, but the vagaries on the stock analysts make us cautious.
Up 9%, HOLD

MER Telemanagement (NASDAQ-MTSL)-Recommended 5/17/2011)
Buy Price-$1.42 (Was $1.50 before adding another $10,000 investment)
Valuation $5.61 (Was $5.11)
Closed down $.03 at $1.42
MER announced a contract extension in August of $2.5 million (minimum). This is almost 50% of MER’s entire market cap.
Earnings in August. Not bad. Sales were just over $3 million and they made over $200,000 or $.05 a share. For the six months they have made $.08 a share (untaxed of course). So MTSL is trading at about 8X untaxed annualized earnings. Oh yeah, they have $.63 a share in cash also (up from $.60 last quarter). Our valuation jumped to $5.61 per share.
EVEN BUY

Harris Interactive (NASDAQ-HPOL)-Recommended 3/3/2010)
Buy Price-$.92
Valuation $2.63 (Was $2.97)
Closed at $.62, up $.05
New CEO is cleaning up. They are closing their Hong Kong, Singapore and Shanghai offices and downsizing their U.K. office. Their will be a restructuring charge in the September quarter of some amount. Nevertheless this will all help to reduce their losses going forward and get this ready to sell.
Old CEO was booted in June and a turnaround guy made CEO. This is good news. He has sold his previous companies.
Latest earnings were not good. Sales fell 7% and they lost $2.3 million or $.04 per share. Our valuation fell to $2.63 per share, still 4X the current price.
Down 27%, HOLD

Concurrent Computer (NASDAQ-CCUR)-Recommended 2/4/2011)
Buy Price-$5.08
Valuation $14.04 (was $18.54, $15.99)
Closed up $.17 at $5.71
Earnings out in August. Sales were down to $15.1 million from $17.3 million and they lost $1.353 million or $.16 a share. Cash per share rose to $3.95 from $3.41. Not a great quarter, but not horrible with the cash rise. Our valuation fell to $14.04-still more than double the current price, and with a huge cash cushion.
In April the company announced that it would not do the stock buy back that Skellig was suggesting. We don’t like buy backs anyway. Hopefully Skellig will keep pushing management to get the share price up. Their ownership is up to 5.86%.
Up 12%, BUY

Astex Pharmaceuticals Inc. (Was SuperGen Inc.) (NASDAQ-ASTX)-Recommended 10/4/2010)
Buy Price-$2.31 (was $2.09 before adding $10,000)
Valuation $3.11 (was $5.21, $4.89, $4.37, $3.48)
Closed up $.18 at $2.21
Company name and trading symbol changed last week.
Earnings out in July. Despite that the quarter results did not include the results of Astex, they provided good guidance of what the second half’s combined results will be. For the latest quarter, revenue rose to $11.7 million from $9.9 million last year and they made $.01 a share versus $.02 last year. This quarter’s results included $1.3 million of expenses related to the merger. So all in all, it was a good quarter. However, our valuation based on this quarter fell to $3.11 as revenues declined from the prior quarters $17 million.
As we suspected, the merger with the revenue poor Astex will hurt our valuation which does not take into account the massive drug pipeline of Astex. It is not easy to find a small drug company that has a pile of cash, is not losing a ton of money and is trading at even close to our valuation.
There are $2 BILLION of potential milestone payments down the road.
Down 4%, HOLD

Performance Technology (PTIX-Recommended 3/30/2010)
Buy Price-$2.70
Valuation $4.87-(was $4.99, $3.79, $3.87, $5.03, $5.98, $7.13)
Closed down $.05 at $2.00
Earnings out in August. Sales up 15% to $8.5 million and they made $300,000 on a non-GAAP basis. Not bad at all. Cash is $1.23 a share and our valuation fell a tad to $4.87
We think we will hold on to this one a bit longer and see if they can get to a consistent profit.
Down 26%, HOLD

Extreme Networks (EXTR-Recommended 3/22/2010)
Buy Price-$3.18 (Was $3.04 before adding another $10,000)
Valuation-$6.45 (was $5.67, $7.36, $7.23, $7.31, $6.82, $6.81)
Closed up $.15 at $2.82
Earnings out in August. Sales rose about 5% from last year to $89 million and they lost $2 million or $.02 a share after about $4 million of non-cash charges. Cash stayed at about $147 million or $1.59 per share. Our valuation moved back up to $6.45 a share.
Big news in July. EXTR announced they are laying off 16% of their employees and expect $20 million of cost reductions in FY 2012 and allow the company to make consistent double digit operating income. We view this all as good news for the future. Starboard was cleared to buy up to 15% of EXTR as disclosed in an SEC filing in June.
Starboard Value Fund filed another 13D/A in June disclosing that they had upped their stake again to 9.6%.
Down 11%, BUY

Broadvision (BVSN-Recommended 3/16/2010)
Buy Price-$13.50
Valuation $18.01-(was $21.21, $22.95, $22.31, $21.77, $23.37, $27.15)
$13.14 per share in cash.
Closed down $.03 at $8.57
Now trading $4.57 below cash value. Nuts.
Earnings in July. Not so hot. Sales were down to $4 million (from $5.1 million last quarter), and they lost $1.5 million. Cash per share fell to $13.14. Clearly their social networking initiative has not taken hold yet. This is still trading like a Chinese stock, but it is a U.S. company and it trading at less than cash value. Our valuation however fell to $18.01. Without the fact that BVSN is trading at less than cash, we would likely sell BVSN but will hold on another quarter or two and see if they can produce some decent results.
Down 36%, BUY

Gravity Company Ltd. (GRVY-Recommended 1/18/2010)
Buy Price-$1.68
Valuation $5.33-(Was $5.61, $5.73, $4.38, $4.44, $5.15)
Closed unchanged at $1.40
Now trading at $.70 less than cash value. And they are profitable.
June quarterly earnings out in August. Revenues were just under $14 million and they made $.06 a share. Only fly in the ointment was that Ragnarok 2 is delayed until at least Q1 2012. Cash per share rose to $2.10.
Our valuation fell a bit to $5.33 on some margin compression, but at less than cash value and 30% of our valuation this is one good lottery ticket if they ever release Ragnarok 2.
Down 17%, HOLD

AEterna Zentaris (AEZS-Recommended 6/20/2009)
Buy price $1.42 (was $1.78 before adding another $10,000, $1.82 before double up)
Valuation –Speculation.
Closed unchanged at $1.88
AEZS announced positive Phase 2 results for AEZS 108 last week. Didn’t seem to matter to investors and we actually lost $.05.
Earnings announced in August. Revenues were up about $900,000 to $6.5 million and their operating loss was about $8 million (compared to $15 million loss last year). AEZS has been diligently selling shares under their announced programs and have about $53 million in cash (but close to 100 million shares outstanding). This is pretty normal for a developing drug company.
Speculative for sure.
Up 32%, HOLD

Spectranetics (SPNC-Recommended 9/2/2006)
Buy price $5.68 (was $8.90, $9.40 before adding $10,000, and was $10.65 before double up),
Valuation –$10.00
Closed up $.62 at $6.72
SPNC filed an 8k late on Friday. They lost another lawsuit. This one will only cost about $800,000. They may appeal and burn more legal fees. I hope the new CEO straightens these jokers out.
Earnings out in July. Sales rose 7% to $32.2 million and they actually managed a $.02 profit. Cash rose to $35.7 million.
SPNC announced recently that they finally hired a new CEO. He comes from DaVita, but we were not all that impressed with his resume. I hope he is planning on making a big killing on his stock options at SPNC and not just continuing to screw up like the other current and previous management.
Paragon filed a 13D/A in May disclosing they had upped their stake to 7%.
Up 18%, HOLD

Mediware (MEDW-Recommended 6/4/2007)
Buy Price $6.33, (was $6.52, $6.67 ($10,000 added), $6.98 after double up)
Valuation $18.34 (was $16.07, $15.04, $14.23, $15.02, $14.35, $12.13, $12.57, $12.29, $11.90, $11.30, $11.48, $11.47 $10.99, $10.28, $13.32, $12.89, $13.40)
Closed down $.12 at $11.10
Earnings out in September. Revenues up 20% and EPS more than doubled to $.25 a share. Cash remained at $3.66 a share and our valuation jumped to $18.34.
Constellation resumed selling in early September.
We give up on the sale of the company anytime soon.
Constellation Software owns 21.8%, but put itself up for sale this year. Should have bought Constellation stock, it has tripled since they got into MEDW!
All we read is that medical records will be a hot area, so MEDW looks like the place to be.
Up 75%, HOLD

Vertro (VTRO (was-MIVA)-Recommended 10/21/2007)
Buy Price $8.15 (Was $11.90 before adding another $20,000, $13.10 before another $10,000 and was $15.00 before double up),
Valuation $10.91 (was $12.42, $14.23, $14.76, $12.40, $12.55, $10.85, $8.25, $9.45, $28.05, $32.10, $34.20, $37.90, $37.95)
Closed up $.35 at $1.75
VTRO announced last week that their new homepage was generating 30% higher revenue per install. They needed some good news here.
Earnings announced in August. Not great. Sales were down $1 million from last year to $7.5 million and they lost $300,000 ($.05 per share).
Should have sold this when it traded over $6. Our valuation fell to $10.91 and cash per share fell to $.67.
Down 79% HOLD

Angeion Corporation (ANGN-Recommended 8/28/2008)
Buy Price-$3.82 (was $5.15 before $10,000 added)
Valuation $13.13 (was $13.19, $13.60, $15.00, $13.06, $12.15, $11.29, $11.73, $11.47, $11.16, $9.53, $13.30, $13.03)
Closed up $.44 at $4.33
CEO bought 10,000 shares last week at $4.25. Good sign.
Earnings in August. Another lackluster quarter. Sales fell from $7.1 million to $6.8 million and they lost $81,000 or $.02 a share. Our valuation fell slightly to $13.13 and cash was $2.39 per share. If this company could just show a bit of growth I think we would see $10 in short order—if.
Blueline Partners still owns 7.6% of ANGN and ought to be pushing on the company to do something about the stock price.
Up 13%, BUY

OB-abies (Bulletin Board Listed Stocks)

As proven by OPTIO, patience is necessary with these stocks.

ARI Networks (ARIS.ob-Recommended 8/19/2006)
Buy price $1.61 (Was $1.78 before another $10,000 added, was $2.06 before double up),
Valuation $5.65 (was $5.39, $4,86, $5.60, $5.73, $5.54, $5.74, $5.96, $4.72, $5.19, $5.66, $5.63, $5.61, $5.71, $5.49, $5.34, $5.03, $5.28, $5.28, $5.21)
Closed at $.80 up $.05.
Earnings out in June. Sales were flat at $5.354 million, operating income however jumped to $675,000 from $297,000 and they made $.07 per share (about $.04 excluding non-recurring and discontinued operations). Our valuation jumped back up to $5.65 on higher than expected margins. If they can maintain $.04 per quarter (fully taxed), we should be on our way to having a winner here.
Wake up management–you have a great little company here worth 6X what it is selling for.
Now down 50%, BUY, Still a Huge valuation gap here.

Rand Worldwide (RWWI.ob (Was Avatech, AVSO.ob)-Bought November 28, 2005)
Buy price $.79 (Was $.93, $.99 and $1.19 before adding $10,000-each time),
Valuation $2.60 (was $2.40, $1.90, $2.26 $3.07, $3.03, $2.38, $2.57, $2.81, $2.78, $3.30, $3.76, $4.00 $3.41, $3.05, $2.53, $3.25, $3.29 $2.69, $3.36, $3.81)
Stock closed at $.75, up $.03
Earnings out in May. Sales were $27.4 million and they made $.04 a share. Our valuation jumped to $2.60 a share. Hopefully another quarter or two of positive results will get this over $1.50.
Down 5%, HOLD

CTI Holdings (CTIG.ob-Recommended 2/25/2006)
Buy price $.27 ask,
Valuation $1.23 (Was $.91, $1.21, $.71, $.83, $.88 $.96, $.93, $.75, $.85, $1.57, $1.40, $1.29, $1.38, $1.31, $1.38, $1.29, $1.42, $1.28 $1.13, $1.05, $.82)
Ask price $.10, closed at $.08.
CEO bought more shares last week, about 40,000 in total.
One of CTI’s directors bought 254,000 shares in August and the CEO bought 38,000 more. Finally, some trading activity!
Earnings announced in August. Not bad at all. .Revenues increased from $3.578 million to $4 million and they only lost $.01 per share. The good news is that they got a $7 million prepayment on a big U.K. order and were able to pay off all their debt and end up with $4.65 million in net cash. This is $.16 a share—double the current trading price. VOIP revenues more than doubled to $461,000 from $197,000 last year and almost doubled from $246,000 last quarter. VOIP still lost $545,000 but the loss was $100,000 less than last year. Our valuation spiked back up to $1.23.
At a $2.5 million market cap, this is stupidly cheap. Their intellectual property is probably worth 10 times this price. They need to liquefy this value somehow.
They might have to sell or shut this VOIP business down in our opinion. Just losing too much money, and eroding shareholder value–or it could be a home run.
Still an “undercover” company and stock.
Down 63%. HOLD

Lotus Pharmaceuticals (LTUS.ob-Recommended 12/3/2007)
Buy price $1.68 (Was $1.80 before $10,000 adder, $2.16 before double-up)
Valuation-$1.05 (Was $2.43, $4.11, $4.84, $4.98, $4.60, $3.82, $4.00, $3.68, $3.12, $3.98, $4.44, $3.22, $2.12, $4.56, $4.16)
Closed at $.37, unchanged.
Last earnings report in August. Sales were down $200,000 to $18.7 million and they made $.06 a share compared to $.24 last year. Our valuation plunged to $1.05 per share on margin and income declines. Gross margins fell to 26% from 48% last year. We are now worried for the first time that with the decline in net income, that they may be having liquidity issues with all of their capital commitments. If this is going to work, it won’t be until 2012 that we see anything.
Down 78%, HOLD

Cheap Stocks, 9/12/2011 Update

Well the market was looking good until Friday. European debt worries, spending another half a trillion dollars to create jobs in the US, how many we weren’t told, whatever. We had an up week, while all the averages were down, but we are still down for the year.

Some of our stocks are just stupid cheap—compared to their cash on hand. Check the list in our posting of 9/2/2011.

We were up .8% last week and are now down 5.8% for the year.

The DOW was down 2.2% last week, NASDAQ was down .5% and the S+P 500 was down 1.7%. The Russell 3000 and the Wilshire 5000 were both down 1.6% for the week

AVSO, BVSN, CCUR, EXTR, RIMG, MTSL and MITL are our favorites.

For the year, the DOW is down 5.1%, NASDAQ is down 7%, S+P 500 is down 8.2%, the Russell 3000 is down 8.8% and the Wilshire is down around 9%.

Last week we went 10 stocks up, 8 down and 3 unchanged. Since inception we are now 50 stocks up and 21 down for a 73% winning percentage (80% is our target win %).

Since our beginning, we have closed out the following positions:

2006-NTCT +44%
2006-ONXS +11% (Buyout offer)
2006-DTLK +41%
2006-CAW +21% (Buyout offer)
2007-IYXI.ob +44% (Buyout offer)
2007-MOBI +47% (Buyout offer)
2007-INFT +11% (Buyout offer)
2007-RITT +62%
2007-MIVA +55%
2007-DTLK +25% (2 weeks)
2007-PDLI + 3%
2007-QADI +25%
2007-CIMT +50%
2007-BDR +19%
2007-LINN.ob -57% (mortgage business bust didn’t help here)
2007-TISA -39% (take some tax loss for 2007 due to disappointing results.
2008-ANGN +26%
2008-OPTO.ob +40% (Buy-out offer)
2008-PDLI +9% (company split, and special dividend)
2008-BDAY -39% (long overdue takeover offer-or “take-under”)
2008-DTLK +40% (third trip on this one)
2008-ILOG +26% (Buy-out offer from IBM)
2008-PARL +56%
2009-MBRK +67%
2009-SNWL +14%
2009-CYNO +25%
2009-DTLK +33%
2009-NED +46%
2009-CUTR +13%
2009-HSTM +67% (continued good earnings)
2009-RNWK +36%
2009-OPK +116%
2009-CLZR -32% (a loser even on a buy-out)
2009-DTLK +28% (our 5th profitable trip on this one)
2010-HPOL +110%
2010-DIVX +25%
2010-CHRD +37% Buyout (2 weeks after we recommended it)
2010-HPOL +30%
2010-MGIC +82%
2010-GSL +78%
2010-CCEL +49%
2010-HPOL +27%
2010-CAW EVEN (excluding 2.5 years of dividends)
2011-DWCH +116%
2011-IPAS +15%
2011-PRM +56% Buyout (1 week after we recommended it)
2011-RST +12%
2011-NINE -10%

The model portfolio assumes $10,000 invested in each stock (unless we double-up–then it is $20,000), less $10 commission each way (TD Ameritrade rate).

For the 48 stocks that we closed out since 2006 (43 were winners) the average net gain was 37%.

Sigma Designs Inc. (NASDAQ-SIGM)-Recommended 7/11/2011)
Buy Price-$8.49
Valuation $13.40 (Was $16.02)
Closed up $.54 at $7.96
Earnings out in August. Sales were down 23% to just under $47 million and they lost $22 million. Yuck. But it is not as bad as it seems. Cash and investments actually went up to $5.40 a share ($170 million) and if you exclude the GAAP non-cash BS and the inventory write down, the loss was “only” about $6 million. So we are trading at a market cap of about $65 million (excluding cash) for a $200 million a year chip company with 50% margins. Still pretty stupid we think. However, our valuation dived to $13.40, so we need to keep our eye on this one.
Down 6%, HOLD

Mitel Networks (NASDAQ-MITL)-Recommended 7/6/2011)
Buy Price- $3.36( Was $3.95 before $10,000 added)
Valuation $14.04 (Was $10.39)
Closed down $.45 at $3.07
No good reason for the decline that we see other than a lousy market and no buyers.
Earnings in August. Pretty good. Revenues were $164 million up from $160 million last year. Non-GAAP net income was $9.2 million or $.16 a share compared to $10.8 million and $.19 a share last year. They took a 44.8 million restructuring charge in the quarter, so they reported a loss of $2.8 million in the quarter.
Our valuation jumped to $14.04.
Down 9%, BUY

Rimage (NASDAQ-RIMG)-Recommended 5/24/2011)
Buy Price-$14.20
Valuation $25.63 (Was $26.45)
Closed up $.08 at $13.01
Yield here is 3.1% and cash is 97% of its market cap.
Earnings out in July. Sales were off about 10% to $20.2 million and earnings were off $.10 to $.12 per share. Cash continued to rise to $119 million ($12.49 per share). Our valuation slipped a bit to $25.63 on the lower sales. With the dividend and a huge cash cushion, we still like RIMG.
Their activist shareholder Arcadia Capital Management sent a letter to the Board in July, suggesting that RIMG should pay out a $9 per share special dividend, and not waste it on some stupid acquisition. We would take the dividend—or a buy-out.
Down 8%, HOLD

Lexmark International (NYSE-LXK)-Recommended 5/24/2011)
Buy Price-$28.80
Valuation $79.12 (Was $63.99)
Closed down $.13 at $30.42
Earnings in July. They were great. They made $1.27 per share earnings on flat sales up from $1.07 in earnings last year. They are projecting $.86-$.96 in earnings for Q3. They seem easily on track to make over $4 per share this year. Our valuation soared to $79.12 per share. PE guys should be drooling over LXK. This would normally be a “buy” with such a huge discount to our valuation, but the vagaries on the stock analysts make us cautious.
Up 6%, HOLD

MER Telemanagement (NASDAQ-MTSL)-Recommended 5/17/2011)
Buy Price-$1.42 (Was $1.50 before adding another $10,000 investment)
Valuation $5.61 (Was $5.11)
Closed up $.15 at $1.45
MER announced a contract extension in August of $2.5 million (minimum). This is almost 50% of MER’s entire market cap.
Earnings in August. Not bad. Sales were just over $3 million and they made over $200,000 or $.05 a share. For the six months they have made $.08 a share (untaxed of course). So MTSL is trading at about 8X untaxed annualized earnings. Oh yeah, they have $.63 a share in cash also (up from $.60 last quarter). Our valuation jumped to $5.61 per share.
Up 2%, BUY

Harris Interactive (NASDAQ-HPOL)-Recommended 3/3/2010)
Buy Price-$.92
Valuation $2.63 (Was $2.97)
Closed at $.62, unchanged
New CEO is cleaning up. They are closing their Hong Kong, Singapore and Shanghai offices and downsizing their U.K. office. Their will be a restructuring charge in the September quarter of some amount. Nevertheless this will all help to reduce their losses going forward and get this ready to sell.
Old CEO was booted in June and a turnaround guy made CEO. This is good news. He has sold his previous companies.
Latest earnings were not good. Sales fell 7% and they lost $2.3 million or $.04 per share. Our valuation fell to $2.63 per share, still 4X the current price.
Down 33%, HOLD

Concurrent Computer (NASDAQ-CCUR)-Recommended 2/4/2011)
Buy Price-$5.08
Valuation $14.04 (was $18.54, $15.99)
Closed up $.09 at $5.54
Another deal announced last week. This one is a multi-year deal with Rogers Communiations of Canada.
Earnings out in August. Sales were down to $15.1 million from $17.3 million and they lost $1.353 million or $.16 a share. Cash per share rose to $3.95 from $3.41. Not a great quarter, but not horrible with the cash rise. Our valuation fell to $14.04-still more than double the current price, and with a huge cash cushion.
Company announced four new sales wins in China in July. The price shot up to as high as $6.89 on the news.
In April the company announced that it would not do the stock buy back that Skellig was suggesting. We don’t like buy backs anyway. Hopefully Skellig will keep pushing management to get the share price up. Their ownership is up to 5.86%.
Up 9%, BUY

SuperGen Inc. (NASDAQ-SUPG)-Recommended 10/4/2010)
Buy Price-$2.31 (was $2.09 before adding $10,000)
Valuation $3.11 (was $5.21, $4.89, $4.37, $3.48)
Closed down $.01 at $2.03
Earnings out in July. Despite that the quarter results did not include the results of Astex, they provided good guidance of what the second half’s combined results will be. For the latest quarter, revenue rose to $11.7 million from $9.9 million last year and they made $.01 a share versus $.02 last year. This quarter’s results included $1.3 million of expenses related to the merger. So all in all, it was a good quarter. However, our valuation based on this quarter fell to $3.11 as revenues declined from the prior quarters $17 million.
As we suspected, the merger with the revenue poor Astex will hurt our valuation which does not take into account the massive drug pipeline of Astex. It is not easy to find a small drug company that has a pile of cash, is not losing a ton of money and is trading at even close to our valuation.
There are $2 BILLION of potential milestone payments down the road.
Down 12%, HOLD

Performance Technology (PTIX-Recommended 3/30/2010)
Buy Price-$2.70
Valuation $4.87-(was $4.99, $3.79, $3.87, $5.03, $5.98, $7.13)
Closed up $.14 at $2.05
Earnings out in August. Sales up 15% to $8.5 million and they made $300,000 on a non-GAAP basis. Not bad at all. Cash is $1.23 a share and our valuation fell a tad to $4.87
We think we will hold on to this one a bit longer and see if they can get to a consistent profit.
Down 24%, HOLD

Extreme Networks (EXTR-Recommended 3/22/2010)
Buy Price-$3.18 (Was $3.04 before adding another $10,000)
Valuation-$6.45 (was $5.67, $7.36, $7.23, $7.31, $6.82, $6.81)
Closed up $.07 at $2.67
Earnings out in August. Sales rose about 5% from last year to $89 million and they lost $2 million or $.02 a share after about $4 million of non-cash charges. Cash stayed at about $147 million or $1.59 per share. Our valuation moved back up to $6.45 a share.
Big news in July. EXTR announced they are laying off 16% of their employees and expect $20 million of cost reductions in FY 2012 and allow the company to make consistent double digit operating income. We view this all as good news for the future. Starboard was cleared to buy up to 15% of EXTR as disclosed in an SEC filing in June.
Starboard Value Fund filed another 13D/A in June disclosing that they had upped their stake again to 9.6%.
Down 16%, BUY

Broadvision (BVSN-Recommended 3/16/2010)
Buy Price-$13.50
Valuation $18.01-(was $21.21, $22.95, $22.31, $21.77, $23.37, $27.15)
$13.14 per share in cash.
Closed down $.25 at $8.60
Now trading $4.54 below cash value. Nuts.
Earnings in July. Not so hot. Sales were down to $4 million (from $5.1 million last quarter), and they lost $1.5 million. Cash per share fell to $13.14. Clearly their social networking initiative has not taken hold yet. This is still trading like a Chinese stock, but it is a U.S. company and it trading at less than cash value. Our valuation however fell to $18.01. Without the fact that BVSN is trading at less than cash, we would likely sell BVSN but will hold on another quarter or two and see if they can produce some decent results.
Down 36%, BUY

Gravity Company Ltd. (GRVY-Recommended 1/18/2010)
Buy Price-$1.68
Valuation $5.33-(Was $5.61, $5.73, $4.38, $4.44, $5.15)
Closed down $.05 at $1.40
Now trading at $.70 less than cash value. And they are profitable.
June quarterly earnings out in August. Revenues were just under $14 million and they made $.06 a share. Only fly in the ointment was that Ragnarok 2 is delayed until at least Q1 2012. Cash per share rose to $2.10.
Our valuation fell a bit to $5.33 on some margin compression, but at less than cash value and 30% of our valuation this is one good lottery ticket if they ever release Ragnarok 2.
Down 17%, HOLD

AEterna Zentaris (AEZS-Recommended 6/20/2009)
Buy price $1.42 (was $1.78 before adding another $10,000, $1.82 before double up)
Valuation –Speculation.
Closed unchanged at $1.93
AEZS is participating in two investment conferences in September, one on the 7th and the other on the 13th.
Earnings announced in August. Revenues were up about $900,000 to $6.5 million and their operating loss was about $8 million (compared to $15 million loss last year). AEZS has been diligently selling shares under their announced programs and have about $53 million in cash (but close to 100 million shares outstanding). This is pretty normal for a developing drug company.
Speculative for sure.
Up 36%, HOLD

Spectranetics (SPNC-Recommended 9/2/2006)
Buy price $5.68 (was $8.90, $9.40 before adding $10,000, and was $10.65 before double up),
Valuation –$10.00
Closed up $.45 at $6.10
SPNC presented at the Stifel Nicolaus Healthcare conference on September 9th. Late volume of Friday kept SPNC stock even for the day, so maybe it was a good presentation.
Earnings out in July. Sales rose 7% to $32.2 million and they actually managed a $.02 profit. Cash rose to $35.7 million.
SPNC announced recently that they finally hired a new CEO. He comes from DaVita, but we were not all that impressed with his resume. I hope he is planning on making a big killing on his stock options at SPNC and not just continuing to screw up like the other current and previous management.
Paragon filed a 13D/A in May disclosing they had upped their stake to 7%.
Up 7%, HOLD

Mediware (MEDW-Recommended 6/4/2007)
Buy Price $6.33, (was $6.52, $6.67 ($10,000 added), $6.98 after double up)
NEW Valuation $18.34 (was $16.07, $15.04, $14.23, $15.02, $14.35, $12.13, $12.57, $12.29, $11.90, $11.30, $11.48, $11.47 $10.99, $10.28, $13.32, $12.89, $13.40)
Closed up $.05 at $11.22
Blow out earnings last week. Revenues up 20% and EPS more than doubled to $.25 a share. Cash remained at $3.66 a share and our valuation jumped to $18.34. The stock jumped to $12.80 and then slumped to end up just a nickel. Frustrating for sure. Constellation resumed selling again last week. This will keep a cap on the stock price.
We give up on the sale of the company anytime soon.
Constellation Software owns 21.8%, but put itself up for sale this year. Should have bought Constellation stock, it has tripled since they got into MEDW!
All we read is that medical records will be a hot area, so MEDW looks like the place to be.
Up 77%, HOLD

Vertro (VTRO (was-MIVA)-Recommended 10/21/2007)
Buy Price $8.15 (Was $11.90 before adding another $20,000, $13.10 before another $10,000 and was $15.00 before double up),
Valuation $10.91 (was $12.42, $14.23, $14.76, $12.40, $12.55, $10.85, $8.25, $9.45, $28.05, $32.10, $34.20, $37.90, $37.95)
Closed down $.07 at $1.40
Earnings announced in August. Not great. Sales were down $1 million from last year to $7.5 million and they lost $300,000 ($.05 per share).
Should have sold this when it traded over $6. Our valuation fell to $10.91 and cash per share fell to $.67.
Down 83% HOLD

Angeion Corporation (ANGN-Recommended 8/28/2008)
Buy Price-$3.82 (was $5.15 before $10,000 added)
Valuation $13.13 (was $13.19, $13.60, $15.00, $13.06, $12.15, $11.29, $11.73, $11.47, $11.16, $9.53, $13.30, $13.03)
Closed up $.04 at $3.89
Earnings in August. Another lackluster quarter. Sales fell from $7.1 million to $6.8 million and they lost $81,000 or $.02 a share. Our valuation fell slightly to $13.13 and cash was $2.39 per share. If this company could just show a bit of growth I think we would see $10 in short order—if.
Blueline Partners still owns 7.6% of ANGN and ought to be pushing on the company to do something about the stock price.
Up 2%, BUY

OB-abies (Bulletin Board Listed Stocks)

As proven by OPTIO, patience is necessary with these stocks.

ARI Networks (ARIS.ob-Recommended 8/19/2006)
Buy price $1.61 (Was $1.78 before another $10,000 added, was $2.06 before double up),
Valuation $5.65 (was $5.39, $4,86, $5.60, $5.73, $5.54, $5.74, $5.96, $4.72, $5.19, $5.66, $5.63, $5.61, $5.71, $5.49, $5.34, $5.03, $5.28, $5.28, $5.21)
Closed at $.75 unchanged.
Earnings out in June. Sales were flat at $5.354 million, operating income however jumped to $675,000 from $297,000 and they made $.07 per share (about $.04 excluding non-recurring and discontinued operations). Our valuation jumped back up to $5.65 on higher than expected margins. If they can maintain $.04 per quarter (fully taxed), we should be on our way to having a winner here.
Wake up management–you have a great little company here worth 6X what it is selling for.
Now down 53%, BUY, Still a Huge valuation gap here.

Rand Worldwide (RWWI.ob (Was Avatech, AVSO.ob)-Bought November 28, 2005)
Buy price $.79 (Was $.93, $.99 and $1.19 before adding $10,000-each time),
Valuation $2.60 (was $2.40, $1.90, $2.26 $3.07, $3.03, $2.38, $2.57, $2.81, $2.78, $3.30, $3.76, $4.00 $3.41, $3.05, $2.53, $3.25, $3.29 $2.69, $3.36, $3.81)
Stock closed at $.72, up $.04
Earnings out in May. Sales were $27.4 million and they made $.04 a share. Our valuation jumped to $2.60 a share. Hopefully another quarter or two of positive results will get this over $1.50.
Down 9%, HOLD

CTI Holdings (CTIG.ob-Recommended 2/25/2006)
Buy price $.27 ask,
Valuation $1.23 (Was $.91, $1.21, $.71, $.83, $.88 $.96, $.93, $.75, $.85, $1.57, $1.40, $1.29, $1.38, $1.31, $1.38, $1.29, $1.42, $1.28 $1.13, $1.05, $.82)
Ask price $.11, closed at $.11.
One of CTI’s directors bought 254,000 shares in August and the CEO bought 38,000 more.
Earnings announced in August. Not bad at all. .Revenues increased from $3.578 million to $4 million and they only lost $.01 per share. The good news is that they got a $7 million prepayment on a big U.K. order and were able to pay off all their debt and end up with $4.65 million in net cash. This is $.16 a share—well above the current trading price. VOIP revenues more than doubled to $461,000 from $197,000 last year and almost doubled from $246,000 last quarter. VOIP still lost $545,000 but the loss was $100,000 less than last year. Our valuation spiked back up to $1.23.
At a $3.0 million market cap, this is stupidly cheap. Their intellectual property is probably worth 10 times this price. They need to liquefy this value somehow.
They might have to sell or shut this VOIP business down in our opinion. Just losing too much money, and eroding shareholder value–or it could be a home run.
Still an “undercover” company and stock.
Down 59%. HOLD

Lotus Pharmaceuticals (LTUS.ob-Recommended 12/3/2007)
Buy price $1.68 (Was $1.80 before $10,000 adder, $2.16 before double-up)
Valuation-$1.05 (Was $2.43, $4.11, $4.84, $4.98, $4.60, $3.82, $4.00, $3.68, $3.12, $3.98, $4.44, $3.22, $2.12, $4.56, $4.16)
Closed at $.37, down $.07
We continue to wait on this one. China Syndrome and declining earnings and capital committments. They are supposed to move into their Bejing building soon, so maybe this will give the stock a lift, otherwise this will be a tax loss candidate soon.
Last earnings report in August. Sales were down $200,000 to $18.7 million and they made $.06 a share compared to $.24 last year. Our valuation plunged to $1.05 per share on margin and income declines. Gross margins fell to 26% from 48% last year. We are now worried for the first time that with the decline in net income, that they may be having liquidity issues with all of their capital commitments. If this is going to work, it won’t be until 2012 that we see anything.
Down 78%, HOLD

Cheap Stocks, 9/2/2011 Update

The week started out well then faded to end up mostly down. The markets seem so undervalued, but there is also no confidence—or buyers it seems. Some of our stocks are just stupid cheap—compared to their cash on hand. Check the list below:

Stock Cash as % of market value

BVSN 148%

GRVY 145%

CCUR 72%

RIMG 97%

MSTL 49%

SUPG 68%

PTIX 64%

EXTR 61%

CTIG 146%

ANGN 61%

We were down .1% last week and are now down 6.5% for the year.

The DOW was down .4% last week, NASDAQ was even and the S+P 500 was down 4.2%. The Russell 3000 and the Wilshire 5000 were both down .2% for the week

AVSO, BVSN, CCUR, EXTR, RIMG, MTSL and MITL are our favorites.

For the year, the DOW is down 2.9%, NASDAQ is down 6.5%, S+P 500 is down 6.7%, the Russell 3000 is down 7.1% and the Wilshire is down around 7.4%.

Last week we went 7 stocks up, 12 down and 2 unchanged. Since inception we are now 50 stocks up and 19 down for a 73% winning percentage (80% is our target win %).

Since our beginning, we have closed out the following positions:

2006-NTCT +44%

2006-ONXS +11% (Buyout offer)

2006-DTLK +41%

2006-CAW +21% (Buyout offer)

2007-IYXI.ob +44% (Buyout offer)

2007-MOBI +47% (Buyout offer)

2007-INFT +11% (Buyout offer)

2007-RITT +62%

2007-MIVA +55%

2007-DTLK +25% (2 weeks)

2007-PDLI + 3%

2007-QADI +25%

2007-CIMT +50%

2007-BDR +19%

2007-LINN.ob -57% (mortgage business bust didn’t help here)

2007-TISA -39% (take some tax loss for 2007 due to disappointing results.

2008-ANGN +26%

2008-OPTO.ob +40% (Buy-out offer)

2008-PDLI +9% (company split, and special dividend)

2008-BDAY -39% (long overdue takeover offer-or “take-under”)

2008-DTLK +40% (third trip on this one)

2008-ILOG +26% (Buy-out offer from IBM)

2008-PARL +56%

2009-MBRK +67%

2009-SNWL +14%

2009-CYNO +25%

2009-DTLK +33%

2009-NED +46%

2009-CUTR +13%

2009-HSTM +67% (continued good earnings)

2009-RNWK +36%

2009-OPK +116%

2009-CLZR -32% (a loser even on a buy-out)

2009-DTLK +28% (our 5th profitable trip on this one)

2010-HPOL +110%

2010-DIVX +25%

2010-CHRD +37% Buyout (2 weeks after we recommended it)

2010-HPOL +30%

2010-MGIC +82%

2010-GSL +78%

2010-CCEL +49%

2010-HPOL +27%

2010-CAW EVEN (excluding 2.5 years of dividends)

2011-DWCH +116%

2011-IPAS +15%

2011-PRM +56% Buyout (1 week after we recommended it)

2011-RST +12%

2011-NINE -10%

The model portfolio assumes $10,000 invested in each stock (unless we double-up–then it is $20,000), less $10 commission each way (TD Ameritrade rate).

For the 48 stocks that we closed out since 2006 (43 were winners) the average net gain was 37%.

Sigma Designs Inc. (NASDAQ-SIGM)-Recommended 7/11/2011)

Buy Price-$8.49

Valuation $13.40 (Was $16.02)

Closed down $.29 at $7.42

Earnings out in August. Sales were down 23% to just under $47 million and they lost $22 million. Yuck. But it is not as bad as it seems. Cash and investments actually went up to $5.40 a share ($170 million) and if you exclude the GAAP non-cash BS and the inventory write down, the loss was “only” about $6 million. So we are trading at a market cap of about $65 million (excluding cash) for a $200 million a year chip company with 50% margins. Still pretty stupid we think. However, our valuation dived to $13.40, so we need to keep our eye on this one.

Down 13%, HOLD

Mitel Networks (NASDAQ-MITL)-Recommended 7/6/2011)

Buy Price- $3.36( Was $3.95 before $10,000 added)

NEW Valuation $14.04 (Was $10.39)

Closed up $.52 at $3.52

Earnings last week. Pretty good. Revenues were $164 million up from $160 million last year. Non-GAAP net income was $9.2 million or $.16 a share compared to $10.8 million and $.19 a share last year. They took a 44.8 million restructuring charge in the quarter, so they reported a loss of $2.8 million in the quarter. The stock actually managed a small gain on Friday amid the carnage, after being up as much as fifty cents early in the day.

Our valuation jumped to $14.04.

UP 5%, BUY

Rimage (NASDAQ-RIMG)-Recommended 5/24/2011)

Buy Price-$14.20

Valuation $25.63 (Was $26.45)

Closed down $1.15 at $12.93

Yield here is 2.9% and cash is 97% of its market cap.

Earnings out in July. Sales were off about 10% to $20.2 million and earnings were off $.10 to $.12 per share. Cash continued to rise to $119 million ($12.49 per share). Our valuation slipped a bit to $25.63 on the lower sales. With the 2.6% dividend and a huge cash cushion, we still like RIMG.

Their activist shareholder Arcadia Capital Management sent a letter to the Board in July, suggesting that RIMG should pay out a $9 per share special dividend, and not waste it on some stupid acquisition. We would take the dividend—or a buy-out.

Down 9%, HOLD

Lexmark International (NYSE-LXK)-Recommended 5/24/2011)

Buy Price-$28.80

Valuation $79.12 (Was $63.99)

Closed up $.19 at $30.55

Earnings in July. They were great. They made $1.27 per share earnings on flat sales up from $1.07 in earnings last year. They are projecting $.86-$.96 in earnings for Q3. They seem easily on track to make over $4 per share this year. Our valuation soared to $79.12 per share. PE guys should be drooling over LXK. This would normally be a “buy” with such a huge discount to our valuation, but the vagaries on the stock analysts make us cautious.

Up 6%, HOLD

MER Telemanagement (NASDAQ-MTSL)-Recommended 5/17/2011)

Buy Price-$1.42 (Was $1.50 before adding another $10,000 investment)

Valuation $5.61 (Was $5.11)

Closed down $.14 at $1.30

MER announced a contract extension in August of $2.5 million (minimum). This is almost 50% of MER’s entire market cap.

Earnings in August. Not bad. Sales were just over $3 million and they made over $200,000 or $.05 a share. For the six months they have made $.08 a share (untaxed of course). So MTSL is trading at about 8X untaxed annualized earnings. Oh yeah, they have $.63 a share in cash also (up from $.60 last quarter). Our valuation jumped to $5.61 per share.

Down 9%, BUY

Harris Interactive (NASDAQ-HPOL)-Recommended 3/3/2010)

Buy Price-$.92

Valuation $2.63 (Was $2.97)

Closed at $.62, up $.03

New CEO is cleaning up. They are closing their Hong Kong, Singapore and Shanghai offices and downsizing their U.K. office. Their will be a restructuring charge in the September quarter of some amount. Nevertheless this will all help to reduce their losses going forward and get this ready to sell.

Old CEO was booted in June and a turnaround guy made CEO. This is good news. He has sold his previous companies.

Latest earnings were not good. Sales fell 7% and they lost $2.3 million or $.04 per share. Our valuation fell to $2.63 per share, still 4X the current price.

Down 33%, HOLD

Concurrent Computer (NASDAQ-CCUR)-Recommended 2/4/2011)

Buy Price-$5.08

Valuation $14.04 (was $18.54, $15.99)

Closed down $.36 at $5.45

Earnings out in August. Sales were down to $15.1 million from $17.3 million and they lost $1.353 million or $.16 a share. Cash per share rose to $3.95 from $3.41. Not a great quarter, but not horrible with the cash rise. Our valuation fell to $14.04-still more than double the current price, and with a huge cash cushion.

Company announced four new sales wins in China in July. The price shot up to as high as $6.89 on the news.

In April the company announced that it would not do the stock buy back that Skellig was suggesting. We don’t like buy backs anyway. Hopefully Skellig will keep pushing management to get the share price up. Their ownership is up to 5.86%.

Up 7%, BUY

SuperGen Inc. (NASDAQ-SUPG)-Recommended 10/4/2010)

Buy Price-$2.31 (was $2.09 before adding $10,000)

Valuation $3.11 (was $5.21, $4.89, $4.37, $3.48)

Closed down $.06 at $2.04

Earnings out in July. Despite that the quarter results did not include the results of Astex, they provided good guidance of what the second half’s combined results will be. For the latest quarter, revenue rose to $11.7 million from $9.9 million last year and they made $.01 a share versus $.02 last year. This quarter’s results included $1.3 million of expenses related to the merger. So all in all, it was a good quarter. However, our valuation based on this quarter fell to $3.11 as revenues declined from the prior quarters $17 million.

As we suspected, the merger with the revenue poor Astex hurt our valuation which does not take into account the massive drug pipeline of Astex. It is not easy to find a small drug company that has a pile of cash, is not losing a ton of money and is trading at even close to our valuation.

There are $2 BILLION of potential milestone payments down the road.

Down 12%, HOLD

Performance Technology (PTIX-Recommended 3/30/2010)

Buy Price-$2.70

Valuation $4.87-(was $4.99, $3.79, $3.87, $5.03, $5.98, $7.13)

Closed down $.11 at $1.91

Earnings out in August. Sales up 15% to $8.5 million and they made $300,000 on a non-GAAP basis. Not bad at all. Cash is $1.23 a share and our valuation fell a tad to $4.87

We think we will hold on to this one a bit longer and see if they can get to a consistent profit.

Down 29%, HOLD

Extreme Networks (EXTR-Recommended 3/22/2010)

Buy Price-$3.18 (Was $3.04 before adding another $10,000)

Valuation-$6.45 (was $5.67, $7.36, $7.23, $7.31, $6.82, $6.81)

Closed down $.24 at $2.60

Earnings out in August. Sales rose about 5% from last year to $89 million and they lost $2 million or $.02 a share after about $4 million of non-cash charges. Cash stayed at about $147 million or $1.59 per share. Our valuation moved back up to $6.45 a share.

Big news in July. EXTR announced they are laying off 16% of their employees and expect $20 million of cost reductions in FY 2012 and allow the company to make consistent double digit operating income. We view this all as good news for the future. Starboard was cleared to buy up to 15% of EXTR as disclosed in an SEC filing in June.

Starboard Value Fund filed another 13D/A in June disclosing that they had upped their stake again to 9.6%.

Down 18%, BUY

Broadvision (BVSN-Recommended 3/16/2010)

Buy Price-$13.50

Valuation $18.01-(was $21.21, $22.95, $22.31, $21.77, $23.37, $27.15)

$13.14 per share in cash.

Closed down $.34 at $8.85

Now trading $4.29 below cash value. Nuts.

Earnings in July. Not so hot. Sales were down to $4 million (from $5.1 million last quarter), and they lost $1.5 million. Cash per share fell to $13.14. Clearly their social networking initiative has not taken hold yet. This is still trading like a Chinese stock, but it is a U.S. company and it trading at less than cash value. Our valuation however fell to $18.01. Without the fact that BVSN is trading at less than cash, we would likely sell BVSN but will hold on another quarter or two and see if they can produce some decent results.

Down 34%, BUY

Gravity Company Ltd. (GRVY-Recommended 1/18/2010)

Buy Price-$1.68

Valuation $5.33-(Was $5.61, $5.73, $4.38, $4.44, $5.15)

Closed down $.05 at $1.45

Trading at just 70% of cash value.

June quarterly earnings out in August. Revenues were just under $14 million and they made $.06 a share. Only fly in the ointment was that Ragnarok 2 is delayed until at least Q1 2012. Cash per share rose to $2.10.

Our valuation fell a bit to $5.33 on some margin compression, but at less than cash value and 30% of our valuation this is one good lottery ticket if they ever release Ragnarok 2.

Down 14%, HOLD

AEterna Zentaris (AEZS-Recommended 6/20/2009)

Buy price $1.42 (was $1.78 before adding another $10,000, $1.82 before double up)

Valuation –Speculation.

Closed up $.11 at $1.93

AEZS is participating in two investment conferences in September, one on the 7th and the other on the 13th.

Earnings announced in August. Revenues were up about $900,000 to $6.5 million and their operating loss was about $8 million (compared to $15 million loss last year). AEZS has been diligently selling shares under their announced programs and have about $53 million in cash (but close to 100 million shares outstanding). This is pretty normal for a developing drug company.

Speculative for sure.

Up 36%, HOLD

Spectranetics (SPNC-Recommended 9/2/2006)

Buy price $5.68 (was $8.90, $9.40 before adding $10,000, and was $10.65 before double up),

Valuation –$10.00

Closed down $.37 at $5.65

SPNC is presenting at the Stifel Nicolaus Healthcare conference on September 9th.

Earnings out in July. Sales rose 7% to $32.2 million and they actually managed a $.02 profit. Cash rose to $35.7 million.

SPNC announced recently that they finally hired a new CEO. He comes from DaVita, but we were not all that impressed with his resume. I hope he is planning on making a big killing on his stock options at SPNC and not just continuing to screw up like the other current and previous management.

Paragon filed a 13D/A in May disclosing they had upped their stake to 7%.

Down 1%, HOLD

Mediware (MEDW-Recommended 6/4/2007)

Buy Price $6.33, (was $6.52, $6.67 ($10,000 added), $6.98 after double up)

Valuation $16.07 (was $15.04, $14.23, $15.02, $14.35, $12.13, $12.57, $12.29, $11.90, $11.30, $11.48, $11.47 $10.99, $10.28, $13.32, $12.89, $13.40)

Closed up $.84 at $11.17

Earnings due our Wednesday, September 7th before the market opens.

Earnings reported in May. Good again. Sales up 8% and they made $.17 per share up from $.11 last year. Our valuation rose to $16.07 per share. They have $3.66 per share in cash.

MEDW announced what sounded like a nice military contract win in April. No details though, so hard to get too excited. Hopefully this and the acquisition will keep their sales and earnings momentum going.

MEDW announced another acquisition in March. No details of what it cost, or what it will do to earnings.

We give up on the sale of the company anytime soon.

Constellation Software owns 21.8%, but put itself up for sale this year. Should have bought Constellation stock, it has tripled since they got into MEDW!

All we read is that medical records will be a hot area, so MEDW looks like the place to be.

Up 76%, HOLD



Vertro (VTRO (was-MIVA)-Recommended 10/21/2007)


Buy Price $8.15 (Was $11.90 before adding another $20,000, $13.10 before another $10,000 and was $15.00 before double up),

Valuation $10.91 (was $12.42, $14.23, $14.76, $12.40, $12.55, $10.85, $8.25, $9.45, $28.05, $32.10, $34.20, $37.90, $37.95)

Closed unchanged at $1.47

Earnings announced in August. Not great. Sales were down $1 million from last year to $7.5 million and they lost $300,000 ($.05 per share).

Should have sold this when it traded over $6. Our valuation fell to $10.91 and cash per share fell to $.67.

Down 82%, HOLD

Angeion Corporation (ANGN-Recommended 8/28/2008)

Buy Price-$3.82 (was $5.15 before $10,000 added)

NEW Valuation $13.13 (was $13.19, $13.60, $15.00, $13.06, $12.15, $11.29, $11.73, $11.47, $11.16, $9.53, $13.30, $13.03)

Closed down $.18 at $3.85

Earnings out last week. Another lackluster quarter. Sales fell from $7.1 million to $6.8 million and they lost $81,000 or $.02 a share. Our valuation fell slightly to $13.13 and cash was $2.39 per share. If this company could just show a bit of growth I think we would see $10 in short order—if.

Blueline Partners still owns 7.6% of ANGN and ought to be pushing on the company to do something about the stock price.

Up 1%, BUY

OB-abies (Bulletin Board Listed Stocks)

As proven by OPTIO, patience is necessary with these stocks.

ARI Networks (ARIS.ob-Recommended 8/19/2006)

Buy price $1.61 (Was $1.78 before another $10,000 added, was $2.06 before double up),

Valuation $5.65 (was $5.39, $4,86, $5.60, $5.73, $5.54, $5.74, $5.96, $4.72, $5.19, $5.66, $5.63, $5.61, $5.71, $5.49, $5.34, $5.03, $5.28, $5.28, $5.21)

Closed at $.75 up $.09

Earnings out in June. Sales were flat at $5.354 million, operating income however jumped to $675,000 from $297,000 and they made $.07 per share (about $.04 excluding non-recurring and discontinued operations). Our valuation jumped back up to $5.65 on higher than expected margins. If they can maintain $.04 per quarter (fully taxed), we should be on our way to having a winner here.

Wake up management–you have a great little company here worth 6X what it is selling for.

Now down 53%, BUY. Still a Huge valuation gap here.

Rand Worldwide (RWWI.ob (Was Avatech, AVSO.ob)-Bought November 28, 2005)

Buy price $.79 (Was $.93, $.99 and $1.19 before adding $10,000-each time),

Valuation $2.60 (was $2.40, $1.90, $2.26 $3.07, $3.03, $2.38, $2.57, $2.81, $2.78, $3.30, $3.76, $4.00 $3.41, $3.05, $2.53, $3.25, $3.29 $2.69, $3.36, $3.81)

Stock closed at $.68, down $.07

Earnings out in May. Sales were $27.4 million and they made $.04 a share. Our valuation jumped to $2.60 a share. Hopefully another quarter or two of positive results will get this over $1.50.

Down 14%, HOLD

CTI Holdings (CTIG.ob-Recommended 2/25/2006)

Buy price $.27 ask,

Valuation $1.23 (Was $.91, $1.21, $.71, $.83, $.88 $.96, $.93, $.75, $.85, $1.57, $1.40, $1.29, $1.38, $1.31, $1.38, $1.29, $1.42, $1.28 $1.13, $1.05, $.82)

Ask price $.11, closed at $.11.

One of CTI’s directors bought 254,000 shares last week and the CEO bought 38,000 more. Finally, some trading activity!

Earnings announced in August. Not bad at all. .Revenues increased from $3.578 million to $4 million and they only lost $.01 per share. The good news is that they got a $7 million prepayment on a big U.K. order and were able to pay off all their debt and end up with $4.65 million in net cash. This is $.16 a share—double the current trading price. VOIP revenues more than doubled to $461,000 from $197,000 last year and almost doubled from $246,000 last quarter. VOIP still lost $545,000 but the loss was $100,000 less than last year. Our valuation spiked back up to $1.23.

At a $2.5 million market cap, this is stupidly cheap. Their intellectual property is probably worth 10 times this price. They need to liquefy this value somehow.

They might have to sell or shut this VOIP business down in our opinion. Just losing too much money, and eroding shareholder value–or it could be a home run.

Still an “undercover” company and stock.

Down 59%. HOLD

Lotus Pharmaceuticals (LTUS.ob-Recommended 12/3/2007)

Buy price $1.68 (Was $1.80 before $10,000 adder, $2.16 before double-up)

Valuation-$1.05 (Was $2.43, $4.11, $4.84, $4.98, $4.60, $3.82, $4.00, $3.68, $3.12, $3.98, $4.44, $3.22, $2.12, $4.56, $4.16)

Closed at $.44, up $.04

Last earnings report in August. Sales were down $200,000 to $18.7 million and they made $.06 a share compared to $.24 last year. Our valuation plunged to $1.05 per share on margin and income declines. Gross margins fell to 26% from 48% last year. We are now worried for the first time that with the decline in net income, that they may be having liquidity issues with all of their capital commitments. If this is going to work, it won’t be until 2012 that we see anything.

Down 74%, HOLD